The Oxford-linked oncology drug developer has raised the money from new and existing backers, and will use the cash to boost its product pipeline.
Immunocore, a UK-based immunotherapy developer that traces its origins to University of Oxford, has secured $75m in a series C round led by an unnamed returning investor.
The round included accounts and vehicles for investment management firm BlackRock as well as undisclosed existing backers. In addition, Oxford Finance supplied $100m in debt financing.
Immunocore is working on T-cell receptor (TCR)-based drugs, which introduce modified white blood cells in the immune system in a bid to fight infectious and autoimmune diseases and cancers.
The company was set up by biotechnology firm Medigene in 2008 to commercialise aspects of Avidex technology, the latter having been spun out of Oxford in 1999. A sister company, Adaptimmune, was formed concurrently to market other Avidex assets.
The company will leverage the series C cash to further develop its clinical-stage TCR products, including ImmTAX, which treats cancer and viral infections, and Tebentafusp,…
